Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax Immunization to Assess Effects of MVA Vaccination on Dryvax Takes.

Next Previous
Trial Profile

ACAM 3000 MVA (Acambis Modified Vaccinia Ankara) Immunization Followed by Dryvax Vaccination of Healthy Vaccinia-Naïve Adults: A Phase I/II, Placebo-Controlled Study of the Effects of Dose and Route of Administration of MVA on Safety, Reactogenicity and Immunogenicity, Followed by Dryvax Immunization to Assess Effects of MVA Vaccination on Dryvax Takes.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVA 3000 (Primary) ; MVA 3000 (Primary) ; MVA 3000 (Primary) ; Smallpox vaccine
  • Indications Smallpox
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

    • Most Recent Events

    • 10 Mar 2010 Dryvax challenge results published in the Journal of Infectious Diseases.
    • 10 Mar 2010 Immunogenicity and reactogenicity results published in the Journal of Infectious Diseases.
    • 18 Sep 2008 Primary end point identified as safety as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top